Sustained responses (SR; PCR negative 24 weeks after treatment cessation) according to genotype in naive patients taken from the two multicentre randomised controlled trials published in 1998144 145
| SR | |||||
| IFN/placebo | IFN/ribavirin | ||||
| Study | 24 weeks | 48 weeks | 24 weeks | 48 weeks | |
| Poynard145 | |||||
| Genotype 1 | — | 20/179 (11%) | 32/177 (18%) | 56/180 (31%) | |
| Genotype non-1 | — | 33/99 (33%) | 64/100 (64%) | 62/97 (64%) | |
| McHutchinson145 | |||||
| Genotype 1 | 3/167 (2%) | 11/162 (7%) | 26/164 (16%) | 46/166 (28%) | |
| Genotype non-1 | 10/64 (16%) | 18/63 (29%) | 44/64 (69%) | 41/61 (66%) | |
| Total | |||||
| Genotype 1 | 3/167 (2%) | 33/341 (10%) | 58/341 (17%) | 102/346 (29%) | |
| Genotype non-1 | 10/64 (16%) | 51/162 (31%) | 110/164 (67%) | 103/158 (65%) | |